Long-term outcome of using Ara-C or not in children’s APL
The use of cytarabine (Ara-C) in treating acute promyelocytic leukemia (APL) is controversial. This study was conducted to demonstrate the effect of treatment with or without Ara-C on long-term event-free survival (EFS) or overall survival (OS). All patients received all-trans retinoic acid (ATRA) +...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health
2025-06-01
|
| Series: | Blood Science |
| Online Access: | http://journals.lww.com/10.1097/BS9.0000000000000225 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850171443922337792 |
|---|---|
| author | Yingjin Zhang Changwen Xue Chao Wu Wenyu Yang Yao Zou Ye Guo Yumei Chen Xiaojuan Chen Xiaofan Zhu Li Zhang |
| author_facet | Yingjin Zhang Changwen Xue Chao Wu Wenyu Yang Yao Zou Ye Guo Yumei Chen Xiaojuan Chen Xiaofan Zhu Li Zhang |
| author_sort | Yingjin Zhang |
| collection | DOAJ |
| description | The use of cytarabine (Ara-C) in treating acute promyelocytic leukemia (APL) is controversial. This study was conducted to demonstrate the effect of treatment with or without Ara-C on long-term event-free survival (EFS) or overall survival (OS). All patients received all-trans retinoic acid (ATRA) + arsenic trioxide (ATO) induction therapy, followed by the course of idarubicin (IDA) and ATO, then were randomly allocated to 2 groups for consolidation therapy, with patients in the daunorubicin (DNR) group received DNR, in the DNR + Ara-C (DA) group received DNR + Ara-C. Maintenance therapy consisted of oral ATRA, 6-mercaptopurine, and methotrexate for 1.5 years. Thirty patients in DA group and 35 patients in DNR group, all achieved complete remission. At follow-up, there was 1 death and 3 relapses in DNR group, compared to none in DA group. There was no statistically significant difference in EFS (P = 0.140) and OS (P = 0.398) between 2 groups, with EFS being 100% in DA group and 91.4% ± 0.047 in DNR group, and OS being 100% in DA group and 97.1% ± 0.028 in DNR group. Our study found no prognostic significance of Ara-C, this may be related to the small sample size. We still recommend the addition of Ara-C during treatment, which has a more positive impact on early remission and late prognosis of patients. |
| format | Article |
| id | doaj-art-9ee3b537cd8e4f70b3e5452ead33c564 |
| institution | OA Journals |
| issn | 2543-6368 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wolters Kluwer Health |
| record_format | Article |
| series | Blood Science |
| spelling | doaj-art-9ee3b537cd8e4f70b3e5452ead33c5642025-08-20T02:20:16ZengWolters Kluwer HealthBlood Science2543-63682025-06-0172e0022510.1097/BS9.0000000000000225202506000-00010Long-term outcome of using Ara-C or not in children’s APLYingjin Zhang0Changwen Xue1Chao Wu2Wenyu Yang3Yao Zou4Ye Guo5Yumei Chen6Xiaojuan Chen7Xiaofan Zhu8Li Zhang9a State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Chinaa State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Chinaa State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Chinaa State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Chinaa State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Chinaa State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Chinaa State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Chinaa State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Chinaa State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Chinaa State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, ChinaThe use of cytarabine (Ara-C) in treating acute promyelocytic leukemia (APL) is controversial. This study was conducted to demonstrate the effect of treatment with or without Ara-C on long-term event-free survival (EFS) or overall survival (OS). All patients received all-trans retinoic acid (ATRA) + arsenic trioxide (ATO) induction therapy, followed by the course of idarubicin (IDA) and ATO, then were randomly allocated to 2 groups for consolidation therapy, with patients in the daunorubicin (DNR) group received DNR, in the DNR + Ara-C (DA) group received DNR + Ara-C. Maintenance therapy consisted of oral ATRA, 6-mercaptopurine, and methotrexate for 1.5 years. Thirty patients in DA group and 35 patients in DNR group, all achieved complete remission. At follow-up, there was 1 death and 3 relapses in DNR group, compared to none in DA group. There was no statistically significant difference in EFS (P = 0.140) and OS (P = 0.398) between 2 groups, with EFS being 100% in DA group and 91.4% ± 0.047 in DNR group, and OS being 100% in DA group and 97.1% ± 0.028 in DNR group. Our study found no prognostic significance of Ara-C, this may be related to the small sample size. We still recommend the addition of Ara-C during treatment, which has a more positive impact on early remission and late prognosis of patients.http://journals.lww.com/10.1097/BS9.0000000000000225 |
| spellingShingle | Yingjin Zhang Changwen Xue Chao Wu Wenyu Yang Yao Zou Ye Guo Yumei Chen Xiaojuan Chen Xiaofan Zhu Li Zhang Long-term outcome of using Ara-C or not in children’s APL Blood Science |
| title | Long-term outcome of using Ara-C or not in children’s APL |
| title_full | Long-term outcome of using Ara-C or not in children’s APL |
| title_fullStr | Long-term outcome of using Ara-C or not in children’s APL |
| title_full_unstemmed | Long-term outcome of using Ara-C or not in children’s APL |
| title_short | Long-term outcome of using Ara-C or not in children’s APL |
| title_sort | long term outcome of using ara c or not in children s apl |
| url | http://journals.lww.com/10.1097/BS9.0000000000000225 |
| work_keys_str_mv | AT yingjinzhang longtermoutcomeofusingaracornotinchildrensapl AT changwenxue longtermoutcomeofusingaracornotinchildrensapl AT chaowu longtermoutcomeofusingaracornotinchildrensapl AT wenyuyang longtermoutcomeofusingaracornotinchildrensapl AT yaozou longtermoutcomeofusingaracornotinchildrensapl AT yeguo longtermoutcomeofusingaracornotinchildrensapl AT yumeichen longtermoutcomeofusingaracornotinchildrensapl AT xiaojuanchen longtermoutcomeofusingaracornotinchildrensapl AT xiaofanzhu longtermoutcomeofusingaracornotinchildrensapl AT lizhang longtermoutcomeofusingaracornotinchildrensapl |